MedPath

Preventive EXACYL® on Perioperative Bleeding During Orthognathism of Maxillary Surgery

Phase 3
Completed
Conditions
Peri-operative Hemorrhage or Hematoma
Surgery
Retrognathism
Interventions
Drug: saline solution
Registration Number
NCT02702128
Lead Sponsor
University Hospital, Lille
Brief Summary

Prospective, randomized, double-blind, placebo-controlled, mono center, Phase III trial to compare EXACYL in preventive with placebo on perioperatory bleeding in orthognathism surgery.

Detailed Description

The aim of our study was to evaluate the clinical value of preventive treatment EXACYL® on bleeding during surgery to orthognathism. Our hypothesis is that this preventive treatment is not enough reduces bleeding to cause a change in patient management (count additional blood count, extra padding, transfusion).

Prospective equivalence trial type controlled by two parallel group, randomized, triple-blind (patient, surgical team, anesthesia team).

* EXACYL® Group: 1 syringe 1g EXACYL® on one hour + 1 syringe 1g EXACYL® on 8 hours

* Control group: 1 syringe 30 mL of saline on one hour + 1 syringe 30 mL saline on 8 hours Main criteria is amount of blood during the entire hospitalization: bleeding during surgery completed in the amount of blood present in the suction drains and nasogastric tube until ablation thereof.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
157
Inclusion Criteria
  • Patients to be operated on an osteotomy of the maxilla through a orthognathism surgery in the department of surgical specialties Salengro hospital
  • Senior surgeon
  • Hb ≥ 12 g / dL in the preoperative
  • Patient ASA 1 or 2
Exclusion Criteria
  • Patient with coagulation disorders
  • Patients treated with anticoagulant or antiplatelet
  • Patients who require anticoagulation postoperatively
  • Patient with against-indication to EXACYL® ( severe renal failure , convulsions history, history of thromboembolism venous or arterial )
  • Surgery recognized preoperatively as particularly complicated by surgeons

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
saline solutionsaline solution30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
Tranexamic acidTranexamic Acid1g of Tranexamic acid on 1hour and 1g of tranexamic acid on 8 hours
Primary Outcome Measures
NameTimeMethod
bleeding perioperativedischarge from the hospital between 2 and 5 days

bleeding during surgery and bleeding after surgery until hospitalization discharge

Secondary Outcome Measures
NameTimeMethod
bleeding during surgeryend of the surgery

Amount of blood during surgery including : blood in the surgical aspiration, in compresses ( assessed by weighing compresses ) in the anesthetic aspiration (when extubation ) and the nasogastric tube at the end of surgery

EVA comfort surgeryend of the surgery

Visual Analogue Scale for evaluation of surgical comfort

Hospitalisation staydischarge from the hospital between 2 and 5 days

Hospitalization stay on day

operative timeend of the surgery

duration in minute of the surgery

EVA comfort patientday 1 after surgery

Visual Analogue Scale for assessment of patient comfort in day 1

Number of red blood cell transfuseddischarge from the hospital between 2 and 5 days

Number of red blood cell transfused

Delta hemoglobinDay 1 after surgery

Difference between preoperative hemoglobin and postoperative ( Measured on the first preoperative and the second on the assessment conducted on Day 1)

EVA fatigue patientdischarge from the hospital between 2 and 5 days

visual analogue scale for assessment of the fatigue of the patient to the hospital discharge

Thrombotic complicationsdischarge from the hospital between 2 and 5 days

Number of thrombotic complications or cardiac complications during the hospitalization

Incidence of nausea and vomitingdischarge from the hospital between 2 and 5 days

Incidence of nausea and vomiting calculated by the anti emetic dose received by the patient during hospitalisation

Trial Locations

Locations (1)

Hôpital Roger Salengro, CHRU de Lille

🇫🇷

Lille, France

Hôpital Roger Salengro, CHRU de Lille
🇫🇷Lille, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.